Genomic and Transcriptomic Approaches Advance the Diagnosis and Prognosis of Neurodegenerative Diseases
Genes · 24.01.2025 · 16 (2) · 135
DOI: 10.3390/genes16020135 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Genes, online erschienen am 24.01.2025. Verfasst von Zheng Liu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Pathology Department, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Hauptthemen laut MEDLINE: Neurodegenerative Diseases, Transcriptome, Genomics. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 127 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), and amyotrophic lateral sclerosis (ALS), represent a growing societal challenge due to their irreversible progression and significant impact on patients, caregivers, and healthcare systems. Despite advances in clinical and imaging-based diagnostics, these diseases are often detected at advanced stages, limiting the effectiveness of therapeutic interventions. Recent breakthroughs in genomic and transcriptomic technologies, including whole-genome sequencing, single-cell RNA sequencing (scRNA-seq), and CRISPR-based screens, have revolutionized the field, offering new avenues for early diagnosis and personalized prognosis. Genomic approaches have elucidated disease-specific genetic risk factors and molecular pathways, while transcriptomic studies have identified stage-specific biomarkers that correlate with disease progression and severity. Furthermore, genome-wide association studies (GWAS), polygenic risk scores (PRS), and spatial transcriptomics are enabling the stratification of patients based on their risk profiles and prognostic trajectories. Advances in functional genomics have uncovered actionable targets, such as ATXN2 in ALS and TREM2 in AD, paving the way for tailored therapeutic strategies. Despite these achievements, challenges remain in translating genomic discoveries into clinical practice due to disease heterogeneity and the complexity of neurodegenerative pathophysiology. Future integration of genetic technologies holds promise for transforming diagnostic and prognostic paradigms, offering hope for improved patient outcomes and precision medicine approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pathology Department, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Department of Neuroscience, Baylor College of Medicine, Houston, TX 77030, USA.
ORCID-Profile: Zheng Liu
Zitieren
APA
Liu, Z., & Song, S. Y. (2025). Genomic and Transcriptomic Approaches Advance the Diagnosis and Prognosis of Neurodegenerative Diseases. Genes, 16(2), 135. https://doi.org/10.3390/genes16020135
Vancouver
Liu Z, Song SY. Genomic and Transcriptomic Approaches Advance the Diagnosis and Prognosis of Neurodegenerative Diseases. Genes. 2025;16(2):135. doi:10.3390/genes16020135
BibTeX
@article{Liu2025,
author = {Liu, Zheng and Song, Si-Yuan},
title = {Genomic and Transcriptomic Approaches Advance the Diagnosis and Prognosis of Neurodegenerative Diseases},
journal = {Genes},
year = {2025},
volume = {16},
number = {2},
pages = {135},
doi = {10.3390/genes16020135}
}
EUVIMED